Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17843355 | 0.89 | RORC (0.77) | RORCIL17A | |
| SCHEMBL17860850 | 0.84 | RORC (0.81) | RORCIL17A | |
| SCHEMBL17861009 | 0.82 | RORC (1.00) | RORCIL17A | |
| SCHEMBL20684155 | 0.80 | RORC (0.48) | RORCIL17A | |
| SCHEMBL17843386 | 0.80 | RORC (0.67) | RORCIL17A | |
| SCHEMBL17860843 | 0.80 | RORC (0.75) | RORCIL17A | |
| SCHEMBL17843342 | 0.79 | RORC (1.00) | RORCIL17A | |
| SCHEMBL17843384 | 0.78 | RORC (0.86) | RORCIL17A | |
| SCHEMBL17861006 | 0.78 | RORC (1.00) | RORCIL17A | |
| SCHEMBL20684174 | 0.78 | RORC (0.85) | RORCIL17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457637-B2 | Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-10-29 | — | — | US | claimed |
| EP-3233848-B1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | claimed |
| US-20180170869-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-06-21 | — | — | US | claimed |
| US-10457637-B2 | Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-10-29 | — | — | US | disclosed |
| US-10457637-B2 | Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-10-29 | — | — | US | disclosed |
| EP-3233848-B1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | disclosed |
| EP-3233848-B1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | disclosed |
| US-20180170869-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20180170869-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-06-21 | — | — | US | disclosed |
| EP-3233848-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | Galderma Research & Development (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097389-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097389-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170869-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | RORB, RORA, RORC | RORC 3/4885IL17A 180/4885 |
| US-10457637-B2 | Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) | RORB, RORA, RORC | RORC 3/4885IL17A 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.